Logo

SYRA

Syra Health Corp. Class A Common Stock

SYRA

Syra Health Corp. Class A Common Stock • NASDAQ
$0.07 ▼ -10.71% (-0.01)
Market Cap $850438
52w High $0.94
52w Low $0.03
Dividend Yield 0%
P/E -0.94
Volume 8.95K
Outstanding Shares 11.34M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.688M ▼ $786.712K ▼ $-225.902K ▼ -13.383% ▼ $-0.019 ▼ $-221.806K ▼
Q2-2025 $1.946M ▲ $816.053K ▼ $-63.596K ▲ -3.268% ▲ $-0.01 ▲ $-53.76K ▲
Q1-2025 $1.858M ▼ $1.062M ▲ $-472.265K ▲ -25.421% ▼ $-0.065 ▲ $-462.239K ▲
Q4-2024 $2.007M ▼ $957.039K ▼ $-504.397K ▼ -25.135% ▼ $-0.069 ▼ $-491.591K ▼
Q3-2024 $2.253M $1.097M $-417.535K -18.53% $-0.058 $-389.728K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.977M ▼ $3.263M ▼ $1.054M ▼ $2.209M ▼
Q2-2025 $2.306M ▼ $3.471M ▼ $1.057M ▼ $2.414M ▼
Q1-2025 $2.491M ▲ $3.723M ▲ $1.266M ▲ $2.457M ▼
Q4-2024 $2.395M ▼ $3.679M ▼ $800.761K ▼ $2.879M ▼
Q3-2024 $2.697M $4.425M $1.094M $3.331M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $214.899K ▲ $-102.065K ▼ $0 $-109.921K ▲ $-514.04K ▼ $-102.065K ▼
Q2-2025 $-63.596K ▲ $-72.477K ▼ $0 $-112.184K ▼ $-184.661K ▼ $-72.477K ▼
Q1-2025 $-472.265K ▲ $158.231K ▲ $0 $-63.051K ▲ $95.18K ▲ $158.231K ▲
Q4-2024 $-504.397K ▼ $-214.72K ▲ $0 $-87.334K ▼ $-302.054K ▼ $-214.72K ▲
Q3-2024 $-417.535K $-413.301K $0 $1.516M $1.103M $-413.3K

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Population Health
Population Health
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Syra Health looks like a very early‑stage company from an income‑statement perspective. Reported revenue so far is minimal, and the company has been running net losses each year, which is typical for a young, growth‑oriented health‑tech firm. The loss per share has been meaningful, reflecting that spending on building products, technology, and market presence is still well ahead of revenue. With almost no detail on margins in the data provided, the main takeaway is that the business model is not yet proven at scale and profitability is still some distance away.

Balance Sheet

Balance Sheet The balance sheet information in this snapshot is essentially blank, so it’s hard to draw firm conclusions about assets, cash, debt, or capital strength. As a recently listed, smaller healthcare technology company, it is likely operating with a relatively lean asset base and relying on equity capital, but that is not clear from the figures shown. The key uncertainty here is how much financial cushion the company has to fund its growth plans and absorb ongoing losses, since leverage, liquidity, and tangible asset backing are not visible in this data.

Cash Flow

Cash Flow Cash‑flow data is also missing in the summary, so we cannot see how much cash the company is burning or how closely cash outflows track the accounting losses. For a young, loss‑making tech‑enabled healthcare player, it would be reasonable to expect negative operating cash flow as it invests in product development, sales, and infrastructure. Without the actual cash‑flow figures, though, it’s impossible to judge how long existing funding might last, how dependent the firm is on fresh capital, or how near it is to a self‑funding position.

Competitive Edge

Competitive Edge Syra Health is trying to carve out a niche in technology‑enabled behavioral health, digital health, and population health. Its edge comes from combining software, analytics, and service delivery rather than offering a single point solution. Products like its AI‑driven mental health platform, a tailored electronic medical record system for smaller providers, and a multilingual patient‑facing chatbot target real gaps in access, affordability, and workflow. The company also leans on experience with state government contracts and its status as a minority and women‑owned business, which can help in certain public‑sector bids. Against this, it operates in highly competitive arenas—mental health apps, EMR systems, and analytics all have many established players—so scale, trust, and execution will matter a lot for sustaining any advantage.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of the story. Syra is building AI‑enabled tools for proactive mental health care, interoperable medical records for smaller organizations, and population‑health analytics that turn raw data into practical insights. Its focus on prevention, multilingual engagement, and customization for underserved segments helps differentiate it from more generic health‑tech offerings. The company also signals an active pipeline of new products and continued use of AI and machine learning, supported by recognized data‑security standards. The opportunity is that successful rollout could create high‑margin, sticky platforms; the risk is that R&D and commercialization costs remain high while adoption takes time, especially in a cautious, regulated healthcare environment.

Summary

Putting it together, Syra Health is a newly public, innovation‑driven healthcare technology company with a compelling narrative but very early‑stage financials. Revenues remain small, the business is loss‑making, and the available data does not show how strong its financial cushion is or how heavy its cash burn may be. On the strategic side, it targets meaningful problems—mental health, digital health infrastructure for smaller providers, and data‑driven population health—using proprietary, AI‑powered platforms and government‑focused relationships. The long‑term story rests on its ability to turn that innovation and contract expertise into sustained, scalable revenue and, eventually, profitability in a competitive market with significant regulatory and execution risks.

NEWS

November 12, 2025 · 7:55 AM UTC

Syra Health Announces Third Quarter Financial Results: Margins, Profitability Metrics Improve

Read more

November 5, 2025 · 8:55 AM UTC

Syra Health To Announce Third Quarter 2025 Financial Results

Read more